aDepartment of internal Medicine, Teikyo University college of Medicine, Tokyo, bSupport for community Medicine Endowed Chair, Teikyo University college of Medicine, Tokyo, and cDepartment of Nephrology, Tianjin an initial Center Hospital, Tianjin, China

You are watching: Uric acid and kidney disease progression

Treviño-Becerra A, Iseki K (eds): Uric mountain in Chronic Kidney Disease. Contrib Nephrol. Basel,, 2018, vol 192, pp 56-68

Log in come to check if you already have accessibility to this content.

E-mail resolve / User i would Password


FullText & PDF countless re-access via Unrestricted printing, no saving constraints for personal use much more Information" href="#" class="moreInfo" data-toggle="popover" data-placement="right" data-content="Build your personal library: every transactional details are saved to, including post links for easy access any time native anywhere." title="">read an ext


Buy a write-up Bundle (KAB) and profit native a discount!

If friend would prefer to redeem her KAB credit, please log in.


Rent for 48h to see Buy Cloud accessibility for limitless viewing via different tools Synchronizing in the ReadCube Cloud Printing and saving restrictions use

Complete book

Immediate access to all parts of this publication Cover-to-cover layouts may be available Unlimited re-access via Unrestricted printing, no conserving restriction for personal use read much more

Published online: January 23, 2018Cover Date: 2018

Number of publish Pages: 13Number that Figures: 2Number of Tables: 2


Uric acid (UA) stays a risk element for the development of chronic kidney an illness (CKD). Many observational studies showed a slight elevation in the serum UA level and also this independently predicts the incidence and advance of CKD. The recent meta-analysis, however, did no reach the conclusion the urate-lowering therapy with allopurinol retards the development of CKD. The target level that serum UA if treated is one more issue the debate. Our recent analysis by propensity score analysis has displayed that the serum UA must be targeted below 6.0 mg/dL to inhibit the progression towards end-stage renal disease. Underlying mechanisms whereby boost in serum UA induces kidney injury have actually been elucidated in animal models. Hyperuricemic models can lead to systemic hypertension, arteriolosclerosis including afferent arteriolopathy and albuminuria probably as result of the activation that oxidative stress. Discoveries of urate transporters have elucidated the novel mechanism of UA transfer in the kidney and intestine. The intestinal ABCG2 may play a compensatory function in irradiate of reduced renal clearance that UA in CKD model rats, the create of i beg your pardon is not a uremic toxin yet serum UA itself. Insulin directly upregulates URAT1 and downregulates ABCG2 in the kidney tubules, saying a possible link between UA and metabolic syndrome. This evaluation summarizes the recent expertise on the causal effect of serum UA on the kidney injury.

Yang W, Xie D, Anderson AH, Joffe MM, Greene T, Teal V, Hsu CY, Fink JC, that J, Lash JP, Ojo A, Rahman M, Nessel L, Kusek JW, Feldman HI: association of kidney an illness outcomes v risk components for CKD: result from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 2014;63:236-243.
Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease: i m sorry is chasing which? Nephrol Dial Transplant 2013;28:2221-2228.
Yano H, Tamura Y, Kobayashi K, Tanemoto M, Uchida S: Uric acid transporter ABCG2 is increased in the intestine of the 5/6 nephrectomy rat design of chronic kidney disease. Clin Exp Nephrol 2014;18:50-55.
Nagura M, Tamura Y, Kumagai T, Hosoyamada M, Uchida S: Uric mountain metabolism of kidney and intestine in a rat model of chronic kidney disease. Nucleosides Nucleotides main point Acids 2016; 35:550-558.
Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, Tamai I: SGLT2 inhibitor lowers serum uric mountain through modification of uric mountain transport activity in renal tubule by increased glycosuria. Biopharm drug Dispos 2014;35:391-404.
Toyoki D, Shibata S, Kuribayashi-Okuma E, Xu N, Ishizawa K, Hosoyamada M, Uchida S: Insulin stimulates uric mountain reabsorption via regulating urate transporter 1 and also 1 ATP-binding cassette sub-family G member 2. To be J Physiol Renal Physiol 2017;313:F826-F834.
see LC, Kuo CF, Chuang FH, Li HY, Chen YM, Chen HW, Yu KH: Serum uric mountain is independently linked with metabolic syndrome in topics with and also without a low estimated glomerular filtration rate. J Rheumatol 2009;36:1691-1698.
Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, Lanaspa MA, Nakagawa T, Johnson RJ: Uric mountain in metabolic syndrome: native an innocent bystander to a main player. Eur J Intern Med 2016;29:3-8.
Sanchez-Lozada LG, Lanaspa MA, Cristobal-Garcia M, Garcia-Arroyo F, Soto V, Cruz-Robles D, Nakagawa T, Yu MA, Kang DH, Johnson RJ: Uric acid-induced endothelial dysfunction is linked with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol 2012;121:e71-e78.
Chen C-Y, Lv JM, Yao QZ: Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: one overview. Med Sci Monit 2016;22:2501-2512.
Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric mountain in the progression of renal disease. J am Soc Nephrol 2002;13:2888-2897.
Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood press in the rat through a novel crystal-independent mechanism. Hypertension 2001;38:1101-1106.
Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, Johnson RJ: Hyperuricemia reasons glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.
Jalal DI, Maahs DM, Hovind P, Nakagawa T: Uric acid as a mediator that diabetic nephropathy. Semin Nephrol 2011;31:459-465.
Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J: gentle hyperuricemia induces vasoconstriction and also maintains glomerular hypertension in normal and also remnant kidney rats. Kidney Int 2005;67:237-247.
Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH: Uric acid-induced phenotypic change of renal tubular cells as a novel system of chronic kidney disease. To be J Physiol Renal Physiol 2013;304:F471-480.
Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, Roncal C, Johnson RJ, Nakagawa T: effect of lowering uric acid on renal an illness in the type 2 diabetic db/db mice. To be J Physiol Renal Physiol 2009;297:F481-F488.
Diamond JR, Bonventre JV, Karnovsky MJ: A role for oxygen cost-free radicals in aminonucleoside nephrosis. Kidney Int 1986;29:478-483.
Kawamorita Y, Shiraishi T, Tamura Y, Kumagai T, Shibata S, Fujigaki Y, Hosoyamada M, Nakagawa T, Uchida S: Renoprotective result of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats. Physiol Rep 2017;5. Pii: e13358.
Kang DH, Chen W: Uric acid and chronic kidney disease: brand-new understanding of an old problem. Semin Nephrol 2011;31:447-452.
Mende C: administration of chronic kidney disease: the relationship in between serum uric acid and advancement of nephropathy. Adv Ther 2015;32:1177-1191.
Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P: Is hyperuricemia an elevation risk aspect for new-onset chronic kidney disease?: a systematic review and also meta-analysis based on observational cohort studies. BMC Nephrol 2014;15:122.
Yan D, Tu Y, Jiang F, Wang J, Zhang R, sun X, Wang T, Wang S, Bao Y, Hu C, Jia W: Uric acid is independently connected with diabetic kidney disease: a cross-sectional study in a Chinese population. PLoS One 2015;10:e0129797.
Testa A, Mallamaci F, Spoto B, Pisano A, Sanguedolce MC, Tripepi G, Leonardis D, Zoccali C: combination of a polymorphism in a gene encoding a urate transporter through CKD progression. Clin J am Soc Nephrol 2014;9:1059-1065.
Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S: Time to target uric mountain to retard CKD progression. Clin Exp Nephrol 2017;21:182-192.
Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F: Uric mountain as a risk factor for progression of non-diabetic chronic kidney disease? The Mild come Moderate Kidney condition (MMKD) Study. Exp Gerontol 2008;43:347-352.
Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009;53:796-803.
Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T, Shibata S, Fujigaki Y, Hosoyamada M, Kaneko K, Shen ZY, Fujimori S: Targeting uric acid and also the inhibition of progression to end-stage renal disease-a propensity score analysis. PLoS One 2015;10:e0145506.
Siu YP, Leung KT, Tong MK, Kwan TH: usage of allopurinol in slowly the development of renal condition through its capacity to reduced serum uric acid level. Am J Kidney Dis 2006;47:51-59.
Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A: result of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and also proteinuria in patients through normal renal functions. Int Urol Nephrol 2007;39:1227-1233.
Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: impact of allopurinol in chronic kidney disease progression and also cardiovascular risk. Clin J to be Soc Nephrol 2010;5:1388-1393.
Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Perez de Jose A, Cedeno S, Linares T, Luno J: Allopurinol and also progression of CKD and cardiovascular events: permanent follow-up of a randomized clinical trial. Am J Kidney Dis 2015;65:543-549.
Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, pedestrian RJ, Walters G, Johnson DW: effects of uric acid-lowering treatment on renal outcomes: a methodical review and meta-analysis. Nephrol Dial Transplant 2014;29:406-413.
Kanji T, Gandhi M, Clase CM, Yang R: Urate lowering therapy to boost renal outcomes in patients with chronic kidney disease: organized review and also meta-analysis. BMC Nephrol 2015;16:58.
Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Pandey R: Efficacy the febuxostat for slowing the GFR decrease in patients v CKD and also asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. To be J Kidney Dis 2015;66:945-950.
Hosoya T, Kimura K, Itoh S, Inaba M, Uchida S, Tomino Y, Makino H, Matsuo S, Yamamoto T, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H: The effect of febuxostat to stop a more reduction in renal function of patients with hyperuricemia who have actually never had gout and are complicated by chronic kidney an illness stage 3:study protocol because that a multicenter randomized controlled study. Trials 2014;15:26.

See more: Justice For Maggie Nixon And Obama S End Their Summer Vacation

Published online: January 23, 2018Cover Date: 2018

Number of publish Pages: 13Number the Figures: 2Number the Tables: 2